Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. O...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/10374 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729777345232896 |
|---|---|
| author | Stefan D. Anker |
| author_facet | Stefan D. Anker |
| author_sort | Stefan D. Anker |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. Over the years, several CVOTs using different glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors have reported neutral or improved CV risks or hospitalisation for HF. However, these studies included only a small proportion of the patients with baseline HF thus limiting the available evidence. Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication. |
| format | Article |
| id | doaj-art-dd839f2ab3bf4e1e9d6388f31d4cd802 |
| institution | DOAJ |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2019-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-dd839f2ab3bf4e1e9d6388f31d4cd8022025-08-20T03:09:05ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782019-12-0122546747210.14341/DM1037410484Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agentsStefan D. Anker0Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité UniversitätsmedizinType 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. Over the years, several CVOTs using different glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors have reported neutral or improved CV risks or hospitalisation for HF. However, these studies included only a small proportion of the patients with baseline HF thus limiting the available evidence. Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication.https://www.dia-endojournals.ru/jour/article/view/10374cardiovascular outcome trialsdpp-4 inhibitorsglp-1 receptor agonistsheart failuresglt-2 inhibitorstype 2 diabetes mellitus |
| spellingShingle | Stefan D. Anker Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents Сахарный диабет cardiovascular outcome trials dpp-4 inhibitors glp-1 receptor agonists heart failure sglt-2 inhibitors type 2 diabetes mellitus |
| title | Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents |
| title_full | Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents |
| title_fullStr | Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents |
| title_full_unstemmed | Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents |
| title_short | Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents |
| title_sort | heart failure outcomes in patients with type 2 diabetes mellitus findings from the cardiovascular outcome trials of antidiabetes agents |
| topic | cardiovascular outcome trials dpp-4 inhibitors glp-1 receptor agonists heart failure sglt-2 inhibitors type 2 diabetes mellitus |
| url | https://www.dia-endojournals.ru/jour/article/view/10374 |
| work_keys_str_mv | AT stefandanker heartfailureoutcomesinpatientswithtype2diabetesmellitusfindingsfromthecardiovascularoutcometrialsofantidiabetesagents |